High Flow Nasal Cannula Oxygen During Sedation for Video-assisted Thoracoscopic Surgery

Alexandria University

Status and phase: Unknown; Phase 2

Conditions: Respiratory Failure; Chronic Obstructive Pulmonary Disease

Treatments: Combination Product: High flow nasal cannula; Combination Product: CONTROL

Study type: Interventional

Funder types: Other

Identifiers

NCT04520568

0304712

Details and patient eligibility

About

High-flow nasal cannula (HFNC) is a device that delivers10 to 70 L min-1 of heated, humidified 100% oxygen via nasal route. It provides positive airway pressure, decreases dyspnea, decreases the work of breathing, and improves comfort

Full description

Beneficial effects of the HFNC system have been assessed based on 3 physiologic conditions: decreased dead space, a high concentration of inspiratory oxygen, and positive pressure in the oro-laryngeal cavity.Studies have shown that it improves oxygenation in various perioperative settings such as the apneic patients, patients with respiratory failure , and patients undergoing bronchoscopy

Enrollment: 60 estimated patients

Sex: All

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ASA physical status II and III,
• undergoing VATS

Exclusion criteria

• refusal of patients
• extrem of age

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 2 patient groups, including a placebo group

HFNC group

Active Comparator group

Description:

For HFNC group, F\&P AIRVOTM 2 will be adjusted to give the patients the oxygen flow at 50L/min and the FiO2 at 1.0.Then after three minutes of preoxygenation, sedation will be conducted by giving 25 µg fentanyl and a bolus of 1 mg/kg propofol followed by continuous infusion of propofol using a target-controlled infusion system (TCI pump TE371; Terumo Corporation, TokyoJapan).

Treatment:

Combination Product: High flow nasal cannula

control group

Placebo Comparator group

Description:

induction of general anaesthesia will be done using 2 mg/kg propofol and 1 µg/kg fentanyl. Double lumen tube will be facilitated by cisatracurium 0.2 mg/kg. Anaesthesia will be maintained with isoflurane 0.8 %-1% in 100% oxygen and maintenance dose of cisatracurium 0.02 mg/kg when needed. At the end of surgery, residual neuromuscular paralysis will be antagonized with neostigmine 0.05 mg/kg and atropine 0.01 mg/kg.

Treatment:

Combination Product: CONTROL